Home / Health / Teva Halts Phase III Trial of Fremanezumab in Chronic Cluster Headaches

Teva Halts Phase III Trial of Fremanezumab in Chronic Cluster Headaches

Chronic cluster headaches would have been an add-on indication for fremanezumab, which is under FDA review for prevention of migraines, with a PDUFA target decision date of September 16